Medicines For Europe Urges Intervention In Inflation Crisis
Industry Conditions Have Exacerbated Impact Of Ukraine War And COVID-19
Executive Summary
Medicines for Europe has called for alterations to regulations concerning the off-patent drug sector, which it says will allow the industry to respond more effectively to the region’s dramatic rise in inflation.
You may also be interested in...
Ukraine War Puts The Pharmaceutical Industry To The Test
Pharmaceutical leaders are responding to the many and varied challenges arising from the war in Ukraine.
Medicines For Europe Recommends Changes To EU Pharmaceutical Legislation
Medicines for Europe has offered several suggestions to re-evaluate the EU’s pharmaceutical legislation, including moves to allow off-patent competition from day one of exclusivity expiry as well as to ensure a competitive and balanced single market for multi-source medicines. The European off-patent industry body also discussed access issues, unmet medical needs and incentives in its feedback.
Medicines For Europe Calls For Security Of Supply Legislation
Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislature. Without these, additional cost containment measures for off-patent medicines under consideration by member states may ultimately threaten access by making production unsustainable for manufacturers.